NZ589732A - A process for the preparation of the apoptosis promoter abt-263 - Google Patents
A process for the preparation of the apoptosis promoter abt-263Info
- Publication number
- NZ589732A NZ589732A NZ589732A NZ58973209A NZ589732A NZ 589732 A NZ589732 A NZ 589732A NZ 589732 A NZ589732 A NZ 589732A NZ 58973209 A NZ58973209 A NZ 58973209A NZ 589732 A NZ589732 A NZ 589732A
- Authority
- NZ
- New Zealand
- Prior art keywords
- isolating
- chlorophenyl
- hydroxymethylene
- methyl
- dimethylcyclohexanone
- Prior art date
Links
- 230000006907 apoptotic process Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- VWHVRYQCJCNZFJ-VOTSOKGWSA-N (2e)-2-(hydroxymethylidene)-4,4-dimethylcyclohexan-1-one Chemical compound CC1(C)CCC(=O)\C(=C\O)C1 VWHVRYQCJCNZFJ-VOTSOKGWSA-N 0.000 abstract 6
- BQQHFCDTQRVMCG-ZRDIBKRKSA-N (2e)-1-(4-chlorophenyl)-2-(hydroxymethylidene)-4,4-dimethylcyclohexan-1-ol Chemical compound O/C=C/1CC(C)(C)CCC\1(O)C1=CC=C(Cl)C=C1 BQQHFCDTQRVMCG-ZRDIBKRKSA-N 0.000 abstract 3
- ICUYKCFWVCNLNW-UHFFFAOYSA-N 2-(4-chlorophenyl)-5,5-dimethylcyclohexene-1-carbaldehyde Chemical compound C1C(C)(C)CCC(C=2C=CC(Cl)=CC=2)=C1C=O ICUYKCFWVCNLNW-UHFFFAOYSA-N 0.000 abstract 3
- 239000003153 chemical reaction reagent Substances 0.000 abstract 3
- JBZBOOYFIKNESP-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]benzoic acid Chemical compound C1C(C)(C)CCC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C1=CC=C(C(O)=O)C=C1 JBZBOOYFIKNESP-UHFFFAOYSA-N 0.000 abstract 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 abstract 2
- -1 alkyl formate Chemical compound 0.000 abstract 2
- 230000008878 coupling Effects 0.000 abstract 2
- 238000010168 coupling process Methods 0.000 abstract 2
- 238000005859 coupling reaction Methods 0.000 abstract 2
- RALUUCLZSDKDJY-UHFFFAOYSA-N ethyl 4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1N1CCN(CC=2CC(C)(C)CCC=2C=2C=CC(Cl)=CC=2)CC1 RALUUCLZSDKDJY-UHFFFAOYSA-N 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 abstract 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 2
- PXQMSTLNSHMSJB-UHFFFAOYSA-N 4,4-dimethylcyclohexan-1-one Chemical compound CC1(C)CCC(=O)CC1 PXQMSTLNSHMSJB-UHFFFAOYSA-N 0.000 abstract 1
- WDHCLDUKGHLEOU-MRXNPFEDSA-N 4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide Chemical compound FC(F)(F)S(=O)(=O)C1=CC(S(=O)(=O)N)=CC=C1N[C@@H](CSC=1C=CC=CC=1)CCN1CCOCC1 WDHCLDUKGHLEOU-MRXNPFEDSA-N 0.000 abstract 1
- CDEMHJCJMMOFMB-UHFFFAOYSA-M ClC1=CC=C([Mg]Br)C=C1 Chemical compound ClC1=CC=C([Mg]Br)C=C1 CDEMHJCJMMOFMB-UHFFFAOYSA-M 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000003638 chemical reducing agent Substances 0.000 abstract 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical group [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 abstract 1
- OQEHTFFLOHTFSB-UHFFFAOYSA-N ethyl 4-piperazin-1-ylbenzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1N1CCNCC1 OQEHTFFLOHTFSB-UHFFFAOYSA-N 0.000 abstract 1
- 229950004847 navitoclax Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7439008P | 2008-06-20 | 2008-06-20 | |
| US12/486,361 US8168784B2 (en) | 2008-06-20 | 2009-06-17 | Processes to make apoptosis promoters |
| PCT/US2009/047723 WO2009155386A1 (en) | 2008-06-20 | 2009-06-18 | A process for the preparation of the apoptosis promoter abt-263 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ589732A true NZ589732A (en) | 2012-08-31 |
Family
ID=41431910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ589732A NZ589732A (en) | 2008-06-20 | 2009-06-18 | A process for the preparation of the apoptosis promoter abt-263 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8168784B2 (pt) |
| EP (1) | EP2307393B1 (pt) |
| JP (1) | JP5604424B2 (pt) |
| KR (1) | KR20110019440A (pt) |
| CN (1) | CN102131792B (pt) |
| AU (1) | AU2009260044B2 (pt) |
| BR (1) | BRPI0914311A2 (pt) |
| CA (1) | CA2727932A1 (pt) |
| CY (1) | CY1114242T1 (pt) |
| DK (1) | DK2307393T3 (pt) |
| ES (1) | ES2409263T3 (pt) |
| HK (1) | HK1154568A1 (pt) |
| HR (1) | HRP20130635T1 (pt) |
| IL (1) | IL209807A (pt) |
| MX (1) | MX2010014224A (pt) |
| NZ (1) | NZ589732A (pt) |
| PL (1) | PL2307393T3 (pt) |
| PT (1) | PT2307393E (pt) |
| RU (1) | RU2514935C2 (pt) |
| SI (1) | SI2307393T1 (pt) |
| TW (1) | TWI454471B (pt) |
| WO (1) | WO2009155386A1 (pt) |
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US8362013B2 (en) | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
| US8728516B2 (en) * | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| DK2435432T6 (da) * | 2009-05-26 | 2023-12-18 | Abbvie Ireland Unlimited Co | Apoptose-inducerende midler til behandling af cancer og immune og autoimmune sygdomme |
| TWI540132B (zh) * | 2009-06-08 | 2016-07-01 | 亞培公司 | Ｂｃｌ-２族群抑制劑之口服醫藥劑型 |
| TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| NZ598461A (en) * | 2009-09-20 | 2013-12-20 | Abbvie Inc | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases |
| CA2780177A1 (en) * | 2009-12-22 | 2011-06-30 | Abbott Laboratories | Abt-263 capsule |
| UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
| CN101798292A (zh) * | 2010-03-29 | 2010-08-11 | 无锡好芳德药业有限公司 | ABT-263衍生的新型Bcl-2蛋白抑制剂的制备 |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| WO2012080260A1 (en) | 2010-12-13 | 2012-06-21 | Novartis Ag | Dimeric iap inhibitors |
| UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| CN102584744B (zh) * | 2011-01-06 | 2015-07-01 | 上海药明康德新药开发有限公司 | 4-(4-((2-(4-氯苯基)-5,5-二甲基环己基-1-烯)甲基)哌嗪-1-基)苯甲酸的合成方法 |
| JP5898419B2 (ja) * | 2011-06-07 | 2016-04-06 | 公益財団法人相模中央化学研究所 | （トリフルオロメチルスルホニル）ベンゼン誘導体の製造方法 |
| CA2860676A1 (en) | 2012-01-09 | 2013-07-18 | Novartis Ag | Organic compositions to treat beta-catenin-related diseases |
| DK2958907T3 (en) | 2013-02-19 | 2018-06-06 | Novartis Ag | Thus, benzothiophene derivatives and compositions as selective estrogen receptor degraders |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| EP2968590B1 (en) | 2013-03-15 | 2018-09-05 | Novartis AG | Antibody drug conjugates |
| FR3008093B1 (fr) * | 2013-07-04 | 2015-12-11 | Rhodia Operations | Procede de fluoration de composes halogenures de sulfonyle |
| WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| CN105899493B (zh) | 2014-01-17 | 2019-03-29 | 诺华股份有限公司 | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 |
| CN105899491B (zh) | 2014-01-17 | 2019-04-02 | 诺华股份有限公司 | 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物 |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| AU2015211021B2 (en) | 2014-01-28 | 2020-07-02 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| US11331328B2 (en) | 2014-05-05 | 2022-05-17 | Bioventures, Llc | Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents |
| CA2955972A1 (en) | 2014-07-22 | 2016-01-28 | Bioventures, Llc. | Compositions and methods for selectively depleting senescent cells |
| US10786578B2 (en) | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
| WO2016024195A1 (en) | 2014-08-12 | 2016-02-18 | Novartis Ag | Anti-cdh6 antibody drug conjugates |
| UY36401A (es) | 2014-11-14 | 2016-06-30 | Novartis Ag | Conjugados anticuerpos-fármacos |
| CN107108637B (zh) | 2014-12-23 | 2019-10-29 | 诺华股份有限公司 | 三唑并嘧啶化合物及其用途 |
| CN107667092B (zh) | 2015-03-25 | 2021-05-28 | 诺华股份有限公司 | 作为fgfr4抑制剂的甲酰化n-杂环衍生物 |
| US20190194315A1 (en) | 2015-06-17 | 2019-06-27 | Novartis Ag | Antibody drug conjugates |
| EP3310774B1 (en) | 2015-06-19 | 2020-04-29 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| ES2741746T3 (es) | 2015-06-19 | 2020-02-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
| EP3310771B1 (en) | 2015-06-19 | 2020-07-22 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| WO2017037586A1 (en) | 2015-08-28 | 2017-03-09 | Novartis Ag | Combination therapy using pi3k inhbitor and mdm2 inhibitor |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| US11027021B2 (en) | 2016-03-15 | 2021-06-08 | Seagen Inc. | Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors |
| RU2020121147A (ru) | 2016-03-28 | 2021-11-03 | Пресидж Байосайенсиз, Инк. | Фармацевтические комбинации для лечения злокачественной опухоли |
| WO2017184995A1 (en) | 2016-04-21 | 2017-10-26 | Bioventures, Llc | Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof |
| JP6969800B2 (ja) | 2016-05-04 | 2021-11-24 | ジェノシアンス ファルマ | 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体 |
| EA036446B1 (ru) | 2016-06-14 | 2020-11-11 | Новартис Аг | Соединения и композиции для подавления активности shp2 |
| EP3472161B1 (en) | 2016-06-20 | 2020-03-25 | Novartis AG | Triazolopyridine compounds and uses thereof |
| US11091489B2 (en) | 2016-06-20 | 2021-08-17 | Novartis Ag | Crystalline forms of a triazolopyrimidine compound |
| WO2017221100A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Imidazopyrimidine compounds useful for the treatment of cancer |
| JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| EP3592868B1 (en) | 2017-03-06 | 2022-11-23 | Novartis AG | Methods of treatment of cancer with reduced ubb expression |
| WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| CN111107868A (zh) | 2017-05-24 | 2020-05-05 | 诺华股份有限公司 | 抗体细胞因子移植蛋白及使用方法 |
| CA3063983A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
| WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
| US10435389B2 (en) | 2017-09-11 | 2019-10-08 | Krouzon Pharmaccuticals, Inc. | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2 |
| CA3088253A1 (en) | 2018-01-22 | 2019-07-25 | Bioventures, Llc | Bcl-2 proteins degraders for cancer treatment |
| BR112020022092A2 (pt) | 2018-04-29 | 2021-02-02 | Beigene, Ltd. | compostos, método para tratar doenças apoptóticas desreguladas e composição farmacêutica |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CR20210001A (es) | 2018-07-10 | 2021-04-19 | Novartis Ag | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteina con dedos de zinc 2 de la familia ikaros (1kzf2) |
| JP7337174B2 (ja) | 2018-09-18 | 2023-09-01 | ニカング セラピューティクス， インコーポレイテッド | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体 |
| JP2022502496A (ja) | 2018-09-25 | 2022-01-11 | ブラック ダイアモンド セラピューティクス，インコーポレイティド | チロシンキナーゼ阻害剤組成物、作製方法、および使用方法 |
| BR112021005513A2 (pt) | 2018-09-25 | 2021-06-22 | Black Diamond Therapeutics, Inc. | derivados de quinazolina como inibidor de tirosina quinase, composições, métodos de fabricação e uso dos mesmos |
| KR20210068473A (ko) | 2018-09-29 | 2021-06-09 | 노파르티스 아게 | Shp2 활성 억제용 화합물의 제조 방법 |
| WO2020089811A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody drug conjugates |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| CN113195541A (zh) | 2018-12-21 | 2021-07-30 | 诺华股份有限公司 | 针对pmel17的抗体及其缀合物 |
| CN109851535A (zh) * | 2019-01-30 | 2019-06-07 | 天津现代职业技术学院 | 一种制备4-氟-3-(三氟甲磺酰基)苯磺酰胺的方法 |
| EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US20220144807A1 (en) | 2019-02-15 | 2022-05-12 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| TW202045174A (zh) | 2019-02-28 | 2020-12-16 | 日商富士軟片股份有限公司 | 組合醫藥 |
| JP2022542437A (ja) | 2019-08-02 | 2022-10-03 | ランティオペプ ベスローテン ヴェンノーツハップ | 癌の処置に用いるアンジオテンシン２型（ａｔ２）受容体アゴニスト |
| US20220298120A1 (en) | 2019-08-15 | 2022-09-22 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| EP4034535A4 (en) | 2019-09-26 | 2023-11-22 | Novartis AG | AZACHINOLINE COMPOUNDS AND USES THEREOF |
| US11285159B2 (en) | 2019-11-05 | 2022-03-29 | Abbvie Inc. | Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax |
| WO2021123996A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
| WO2021195206A1 (en) | 2020-03-24 | 2021-09-30 | Black Diamond Therapeutics, Inc. | Polymorphic forms and related uses |
| US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
| WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
| AU2021288224A1 (en) | 2020-06-11 | 2023-01-05 | Novartis Ag | ZBTB32 inhibitors and uses thereof |
| CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| US20230270816A1 (en) | 2020-07-06 | 2023-08-31 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| AR123185A1 (es) | 2020-08-10 | 2022-11-09 | Novartis Ag | Compuestos y composiciones para inhibir ezh2 |
| WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
| IL303661A (en) | 2020-12-22 | 2023-08-01 | Nikang Therapeutics Inc | COMPOUNDS FOR BREAKING CYCLIN-DEPENDENT KINASE 2 THROUGH THE UBIQUITIN PROTEOSOME PATHWAY |
| WO2022152821A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| WO2022170052A1 (en) | 2021-02-05 | 2022-08-11 | Black Diamond Therapeutics, Inc. | Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| EP4323349A1 (en) | 2021-04-14 | 2024-02-21 | Monte Rosa Therapeutics AG | Isoindolinone amide compounds useful to treat diseases associated with gspt1 |
| WO2022219407A1 (en) | 2021-04-14 | 2022-10-20 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| BR112023021475A2 (pt) | 2021-04-16 | 2023-12-19 | Novartis Ag | Conjugados anticorpo-fármaco e métodos para produzir os mesmos |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| WO2023284730A1 (en) | 2021-07-14 | 2023-01-19 | Nikang Therapeutics, Inc. | Alkylidene derivatives as kras inhibitors |
| WO2023011488A1 (zh) | 2021-08-02 | 2023-02-09 | 苏州亚盛药业有限公司 | 一种药物组合及其用途 |
| AU2022405016A1 (en) | 2021-12-09 | 2024-06-06 | University Of Florida Research Foundation, Incorporated | Bcl-xl/bcl-2 dual degraders for treatment of cancers |
| US20230303509A1 (en) | 2022-03-28 | 2023-09-28 | Nikang Therapeutics, Inc. | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| WO2023240024A1 (en) | 2022-06-08 | 2023-12-14 | Nikang Therapeutics, Inc. | Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors |
| WO2024023666A1 (en) | 2022-07-26 | 2024-02-01 | Novartis Ag | Crystalline forms of an akr1c3 dependent kars inhibitor |
| WO2024102849A1 (en) | 2022-11-11 | 2024-05-16 | Nikang Therapeutics, Inc. | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004076468A1 (ja) * | 2003-02-25 | 2004-09-10 | Kobe Tennenbutsu Kagaku Kabushiki Kaisha | ビタミンｄ誘導体を合成するための新規な中間体 |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| AU2006297853B2 (en) * | 2005-05-12 | 2010-08-19 | AbbVie Global Enterprises Ltd. | Apoptosis promoters |
| CN101535280B (zh) | 2006-11-15 | 2012-06-27 | 健泰科生物技术公司 | 芳基磺酰胺化合物 |
-
2009
- 2009-06-17 US US12/486,361 patent/US8168784B2/en active Active
- 2009-06-18 RU RU2011101951/04A patent/RU2514935C2/ru not_active IP Right Cessation
- 2009-06-18 EP EP09767695.1A patent/EP2307393B1/en not_active Not-in-force
- 2009-06-18 SI SI200930640T patent/SI2307393T1/sl unknown
- 2009-06-18 JP JP2011514792A patent/JP5604424B2/ja not_active Expired - Fee Related
- 2009-06-18 DK DK09767695.1T patent/DK2307393T3/da active
- 2009-06-18 AU AU2009260044A patent/AU2009260044B2/en not_active Ceased
- 2009-06-18 WO PCT/US2009/047723 patent/WO2009155386A1/en active Application Filing
- 2009-06-18 NZ NZ589732A patent/NZ589732A/xx not_active IP Right Cessation
- 2009-06-18 KR KR1020117001475A patent/KR20110019440A/ko active IP Right Grant
- 2009-06-18 PL PL09767695T patent/PL2307393T3/pl unknown
- 2009-06-18 CN CN200980132472.XA patent/CN102131792B/zh not_active Expired - Fee Related
- 2009-06-18 ES ES09767695T patent/ES2409263T3/es active Active
- 2009-06-18 BR BRPI0914311A patent/BRPI0914311A2/pt not_active IP Right Cessation
- 2009-06-18 CA CA2727932A patent/CA2727932A1/en not_active Abandoned
- 2009-06-18 MX MX2010014224A patent/MX2010014224A/es active IP Right Grant
- 2009-06-18 PT PT97676951T patent/PT2307393E/pt unknown
- 2009-06-19 TW TW098120701A patent/TWI454471B/zh not_active IP Right Cessation
-
2010
- 2010-12-06 IL IL209807A patent/IL209807A/en not_active IP Right Cessation
-
2011
- 2011-08-16 HK HK11108610.0A patent/HK1154568A1/xx not_active IP Right Cessation
-
2013
- 2013-06-18 CY CY20131100489T patent/CY1114242T1/el unknown
- 2013-07-05 HR HRP20130635AT patent/HRP20130635T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102131792A (zh) | 2011-07-20 |
| CA2727932A1 (en) | 2009-12-23 |
| RU2514935C2 (ru) | 2014-05-10 |
| EP2307393A1 (en) | 2011-04-13 |
| WO2009155386A1 (en) | 2009-12-23 |
| JP2011525182A (ja) | 2011-09-15 |
| SI2307393T1 (sl) | 2013-08-30 |
| EP2307393B1 (en) | 2013-04-10 |
| TWI454471B (zh) | 2014-10-01 |
| IL209807A0 (en) | 2011-02-28 |
| KR20110019440A (ko) | 2011-02-25 |
| PL2307393T3 (pl) | 2013-09-30 |
| IL209807A (en) | 2014-08-31 |
| HK1154568A1 (en) | 2012-04-27 |
| CN102131792B (zh) | 2014-05-07 |
| US20090318689A1 (en) | 2009-12-24 |
| AU2009260044B2 (en) | 2013-08-29 |
| HRP20130635T1 (en) | 2013-08-31 |
| CY1114242T1 (el) | 2016-08-31 |
| MX2010014224A (es) | 2011-01-21 |
| US8168784B2 (en) | 2012-05-01 |
| BRPI0914311A2 (pt) | 2019-08-27 |
| TW201002700A (en) | 2010-01-16 |
| PT2307393E (pt) | 2013-06-27 |
| AU2009260044A1 (en) | 2009-12-23 |
| ES2409263T3 (es) | 2013-06-26 |
| DK2307393T3 (da) | 2013-07-15 |
| RU2011101951A (ru) | 2012-07-27 |
| JP5604424B2 (ja) | 2014-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ589732A (en) | A process for the preparation of the apoptosis promoter abt-263 | |
| RS53627B1 (en) | N- (3-Amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors | |
| ME01395B (me) | Postupak za izradu (1s)-4,5-dimetoksi-1-(metilaminometil)benzociklobutanai njegovih aditivnih soli kiselina kao i njegov a primena za sintezu ivabradina i njegovih farmaceutski prihvatljivih aditivnih soli kiselina | |
| CR11780A (es) | Nuevo proceso para la sintesis de ivabradina y sales de adicion resultantes con un acido farmaceuticamente aceptable (solicitud divisonal) | |
| CR20170037A (es) | Forma de dosificación farmaceutica para administración oral de un inhibidor de la familia bcl-2 | |
| NZ585085A (en) | Method of treating arthritis using arylsulfonamide compounds | |
| RS53209B (en) | PHARMACEUTICAL COMPOSITION FOR VIRAL HEPATITIS C PROTEASE INHIBITOR | |
| MX2010005299A (es) | Derivados de bis-(sulfonilamino) en terapia 066. | |
| NZ607794A (en) | N-acylsulfonamide apoptosis promoters | |
| RS52214B (en) | HDAC INHIBITOR PHARMACEUTICAL FORMULATIONS | |
| NO20076498L (no) | Derivater av 4-(2-amino-1-hydroksyetyl)fenol som agonister av den betta2-adrenerge reseptoren | |
| NZ598461A (en) | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases | |
| UY30274A1 (es) | Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones | |
| SV2004001413A (es) | Sales de acido succinico de 5,7,14-triazatetraciclo[10.3.1.2,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas ref.pc23247 | |
| HUP0302553A2 (hu) | Egy izotiazol-4-karbonsavamid sói és eljárás az előállításukra és ezek alkalmazására a túlzott mértékű sejtburjánzás visszaszorítására alkalmas gyógyszerkészítmények előállítására | |
| UA89801C2 (en) | Novel hydantoin derivatives as metalloproteinase inhibitors | |
| BRPI0607811A2 (pt) | derivados de óxido de pirimidina de 2-(4-cianofenilamino) inibidores de hiv, composição farmacêutica compreendendo os mesmo, processo para preparar a referida composição e uso | |
| DE502004008871D1 (de) | Antiandrogene pyrrolidine mit tumorhemmender wirksamkeit | |
| RS53063B (en) | MGLU2 AGONISTS | |
| WO2007066163A3 (en) | Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates | |
| MA33385B1 (fr) | Acide trans-4-[[(5s)-5-[[[3,5-bis (trifluorométhyl) phényl] méthyl] (2-méthyl-2h-tétrazol-5-yl) amino]-2,3,4,5-tétrahydro-7,9-diméthyl-1h-1-benzazépin-1-yl] méthyl]-cyclohexane carboxylique | |
| HUP0202881A2 (hu) | Antisztatikum | |
| TW200700390A (en) | Metabolites for nk-1 antagonists for emesis | |
| EA201000701A1 (ru) | 4-[4-(2-адамантилкарбамоил)-5-трет-бутилпиразол-1-ил]бензойная кислота-465 | |
| PE20081495A1 (es) | Derivados 4,5-difenilpirrol-2-carboxamida como antagonistas de los receptores cb1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 JUN 2016 BY THOMSON REUTERS Effective date: 20130514 |
|
| ASS | Change of ownership |
Owner name: ABBVIE BAHAMAS LTD., BS Effective date: 20130627 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUN 2017 BY THOMSON REUTERS Effective date: 20160512 |
|
| LAPS | Patent lapsed |